Andrew was diagnosed with multiple myeloma in 2013. Andrew went through five cycles of VRD, a stem cell transplant and two years of maintenance with Revlimid. He has been off of all treatment since March of 2016 and remains in complete remission. Andrew has been an avid cyclist for many years and credits his devotion to exercise for his ability to withstand treatment with limited side effects. Since retiring from full-time employment in 2015, Andrew has had more time to ride his bike, having cycled for over 10,000 miles in five of the last seven years despite living in Pennsylvania (where it gets very cold). Andrew rode with Team R2V in 2019 on the ride through Vermont, finishing in Quebec. That ride was difficult, but rewarding, allowing for the development of long-lasting friendships with his teammates. Andrew is looking forward to riding in Maine this summer with the R2V team.
At Janssen Oncology, we’re shaping the future of cancer treatment. In the process, we’re striving to change expectations of what a cancer diagnosis means. Our purpose is driven by an urgency and commitment to bringing transformational cancer solutions to the people who need them. Passionate about our work, we are driven by the personal connection many of us share with the disease. With our partners, we focus on delivering solutions that make a positive impact on human health. We are part of Janssen Biotech, Inc., and the Janssen Pharmaceutical Companies of Johnson & Johnson.
About Janssen OncologyClick below to learn more about a treatment option for multiple myeloma. If you’re also interested in getting more information from Janssen, sign up for ongoing communications.
Learn More
